Navigation Links
Sequenom Announces Formation of Ophthalmology Clinical Advisory Board
Date:10/14/2010

cal degree from the University of Missouri-Columbia. Upon completing her internship at St. John's Mercy Medical Center, Dr. Gehrs finished her post graduate education by completing a residency and fellowship (vitreoretina) at Duke University Eye Center prior to becoming Chief Resident in 1993.

Dr. Gehrs specializes in retina/vitreous diseases and focuses her research in diabetic retinopathy and age-related macular degeneration. She is certified in both the National Board of Medical Examiners and the American Board of Ophthalmology. Dr. Gehrs is an accomplished teacher, frequent lecturer and is very active in several professional associations.

After more than a dozen years as a vitreoretinal faculty member at the University of Iowa, Dr. Gehrs joined the Center for Retina and Macular Disease, in Florida, in 2009. Most recently, Dr. Gehrs has been distinguished as one of the Best Doctors in America for the past four years in a row.

For full biographies on the members of the Ophthalmology clinical advisory board please see http://www.sequenom.com/Home/About-Us/Clinical-Advisory-Boards/Ophthalmology

"We welcome the strong research expertise and clinical experience that Drs. Hageman, Heier, and Gehrs bring to Sequenom's new ophthalmology focused clinical advisory board," said Ronald M. Lindsay, PhD, executive vice president of research and development at Sequenom. "These highly respected experts will play an important advisory role in supporting our diagnostic development programs and product commercialization plans."

About Sequenom Center for Molecular Medicine, LLC

Sequenom Center for Molecular Medicine (Sequenom CMM®) is a wholly-owned subsidiary of Sequenom, Inc., and is CAP accredited and CLIA-certified specialty reference laboratory dedicated to the development and commercialization of laboratory-developed genetic testing
'/>"/>

SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Sequenom to Present at Two Financial Conferences in September
2. Sequenom to Present at Two Financial Conferences in March
3. Sequenom Appoints Two New Board Members
4. SEQUENOM Announces Partnership With GeneWorks for Sales & Marketing of MassARRAY Systems and Applications in Australia
5. SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
6. SEQUENOM Announces Launch of MassARRAY Compact 96 System
7. SEQUENOM to Hold First Quarter 2009 Financial Results Conference Call on April 30
8. Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics
9. Omeros Announces Additional Support from the National Institute on Drug Abuse for Clinical Studies in Addiction Program
10. Fate Therapeutics Announces Collaboration With BD to Develop and Commercialize Induced Pluripotent Stem Cell Technology
11. Osteotech Announces Early Termination of HSR Waiting Period
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... May 4 Environmental Tectonics Corporation,s (NYSE AMEX ... Division announced today the addition of Mr. Ray ... Wyngarden will be responsible for expanding market awareness ... ETC,s other hyperbaric products in the western portion ...
... it has produced a synthetic H1N1 swine flu vaccine, Replikins PanFlu™, ... vaccine based on the same Replikins peptide technology which provided the ... was on its way. , ... London, UK (PRWEB) ...
... YORK and NASSAU, The Bahamas, May 1 Fincor ... Prospero Group (Pink Sheets: PRPG) , a leading company ... the new ACTRx Malaria and Dengue fever treatment. Fincor also ... a majority of ACTRx International Inc., which combines several natural ...
Cached Biology Technology:Environmental Tectonics Corporation Expands BioMedical Systems Division Sales Staff 2Environmental Tectonics Corporation Expands BioMedical Systems Division Sales Staff 3H1N1 Influenza "Swine Flu" Peptide Vaccine Now Available For Testing Worldwide 2Fincor (FINC) Makes a Share Transfer and Enters the Market With ACTRx a New Malaria and Dengue Fever Treatment 2
(Date:4/15/2014)... in nanoparticle form could help reduce side effects by ... years, scientists have developed nanoparticles that deliver one or ... to design particles that can carry any more than ... have devised a new way to build such nanoparticles, ... different drugs. In a paper published in the ...
(Date:4/15/2014)... cuttlefish, squid and octopus has uncovered details of ... they may help in investigating populations of their ... 10 new parasite species− dicyemid mesozoans −, which ... and octopus). They are the very first ... , "Although dicyemid parasites have been studied ...
(Date:4/14/2014)... swallow, but if you,re over 24 years of age ... cognitive motor performance, according to a new Simon Fraser ... doctoral student, associate professor Mark Blair, Thompson,s thesis supervisor, ... student, deliver the news in a just-published PLOS ... the first social science experiments to rest on big ...
Breaking Biology News(10 mins):Targeting cancer with a triple threat 2Targeting cancer with a triple threat 3Bizarre parasite may provide cuttlefish clues 2Study says we're over the hill at 24 2
... research has found that hurricane activity is ,clustered, rather ... ecosystems and human population. The research was carried ... Queensland Global Change Institute and School of Biological Sciences, ... Fellow) at the University of Exeter,s Exeter Climate Systems ...
... multi-disciplinary 5-year project at the University of Nevada, Reno ... $10 million in funding from the National Institutes of ... manipulate the communication between cells that causes human neurological ... of Medicine, the College of Science and the Department ...
... by researchers at The University of Texas at Austin ... a cure for Alzheimer,s disease and help answer one ... The research, led by Cockrell School of Engineering ... Assistant Professor Jon Pierce-Shimomura, aims to prevent degeneration of ...
Cached Biology News:Clustered hurricanes reduce impact on ecosystems 2$10 million grant supports biological sciences team at University of Nevada, Reno 2$10 million grant supports biological sciences team at University of Nevada, Reno 3Reversing aging 2Reversing aging 3Reversing aging 4
Mouse polyclonal antibody raised against a partial recombinant WRB. NCBI Entrez Gene ID = 7485...
...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
Mouse monoclonal antibody raised against a partial recombinant FAAH. NCBI Entrez Gene ID = FAAH...
Biology Products: